Docetaxel is a treatment option following disease progression on a next-generation hormonal agent for patients with mCRPC, but there is an urgent need for more efficacious treatments. 

Prof Daniel Petrylak speaks to ecancer about the use of pembrolizumab plus docetaxel used to treat patients with metastatic castration-resistant prostate cancer. 

The study investigated the efficacy and safety of pembrolizumab plus docetaxel versus placebo plus docetaxel for participants with mCRPC who had received prior NHA therapy. 

Prof Petrylak explains the results saying that the addition of pembrolizumab to docetaxel did not significantly improve rPFS or overall survival for patients with mCRPC. The study also showed that the treatment regimen did not result in a notable increase in treatment-related adverse events.